10-Q: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Clinical Program Update

Sagimet Biosciences announced its third quarter 2024 financial results, highlighted by progress in its Phase 3 clinical program for denifanstat and a Breakthrough Therapy designation from the FDA.

Summary

• Sagimet Biosciences reported a net loss of $14.6 million for the three months ended September 30, 2024, and a net loss of $29.4 million for the nine months ended September 30, 2024.
• The company's research and development expenses increased to $12.7 million for the quarter and $24.2 million for the nine months, primarily due to costs associated with the Phase 3 program for denifanstat.
• General and administrative expenses were $4.2 million for the quarter and $12.0 million for the nine months.
• The company's cash, cash equivalents, and marketable securities totaled $170.0 million as of September 30, 2024.
• Sagimet received Breakthrough Therapy designation from the FDA for denifanstat for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis.
• The company completed successful end-of-Phase 2 interactions with the FDA, supporting the advancement of denifanstat into Phase 3 in MASH.
• The Phase 3 program is expected to initiate by the end of 2024 and will include two trials: FASCINATE-3 and FASCINIT.
• Ascletis, Sagimet's license partner, completed enrollment of 480 patients in a Phase 3 clinical trial for acne in China and expects topline results in the second quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The Breakthrough Therapy designation and progress to Phase 3 are strong positives, but the ongoing losses and need for future capital raises temper the overall sentiment. The company is making progress but still faces significant risks.

Positives

• The company received Breakthrough Therapy designation from the FDA for denifanstat.
• Sagimet completed successful end-of-Phase 2 interactions with the FDA, supporting the advancement of denifanstat into Phase 3 in MASH.
• The company has sufficient cash, cash equivalents, and marketable securities to fund operations for at least the next 12 months.
• Ascletis completed enrollment in a Phase 3 clinical trial for acne, indicating progress in partnered development.

Negatives

• The company reported a net loss of $14.6 million for the quarter and $29.4 million for the nine months ended September 30, 2024.
• Research and development expenses increased significantly due to the Phase 3 program for denifanstat.
• The company has not generated any revenue from product sales and does not expect to for the foreseeable future.

Risks

• The company is dependent on the success of its lead drug candidate, denifanstat.
• The company will require substantial additional capital to fund its research and development and ongoing operating expenses.
• The company's future operating activities, coupled with its plans to raise capital or issue debt financing, may provide additional liquidity in the future, however these actions are not solely within the control of the company.
• The company is subject to risks associated with clinical trials, regulatory approvals, and commercialization of its drug candidates.
• The company is subject to risks associated with reliance on third parties for manufacturing and clinical trials.
• The company's ability to raise additional funds may be adversely impacted by macroeconomic conditions, disruptions to and volatility in the credit and financial markets and geopolitical turmoil.

Future Outlook

The company expects to initiate its Phase 3 program for denifanstat by the end of 2024 and anticipates that its current cash, cash equivalents, and marketable securities will be sufficient to fund operations for at least the next 12 months. The company also expects to continue to incur significant expenses as it advances its drug candidates through clinical trials and pursues regulatory approval.

Management Comments

• Management believes that the company's existing cash, cash equivalents, and marketable securities will be sufficient to fund operating expenses for at least the next 12 months.
• Management expects research and development expenses to increase substantially for the foreseeable future as the company advances its drug candidates into and through clinical trials.

Industry Context

The company's focus on MASH and FASN inhibitors aligns with the growing interest in treatments for metabolic liver diseases. The Breakthrough Therapy designation for denifanstat highlights the potential of this approach in a competitive landscape. The company's partnership with Ascletis also reflects a trend of global collaborations in drug development.

Comparison to Industry Standards

• The company's Phase 2b results for denifanstat show promising efficacy data compared to other MASH treatments in development, particularly in the areas of NAS reduction and fibrosis improvement.
• The Breakthrough Therapy designation is a positive signal, as it indicates the FDA's recognition of the potential for denifanstat to address an unmet medical need.
• The company's cash position of $170 million is relatively strong compared to other clinical-stage biotechs, providing a runway for the Phase 3 program.
• Competitors in the MASH space include companies such as Madrigal Pharmaceuticals, Intercept Pharmaceuticals, and Viking Therapeutics, all of which are also developing treatments for MASH with varying mechanisms of action. Sagimet's FASN inhibitor approach is differentiated from some of these competitors.
• The company's partnership with Ascletis is similar to other biotech companies that seek to expand their reach and development efforts through collaborations.

Related Party Transactions

• The company recognized $0.1 million of expenses related to its portion of expenses owed under the Ascletis license agreement during the nine months ended September 30, 2024.
• The company paid Ascletis $0.2 million under the Ascletis manufacturing arrangement during the nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders may be encouraged by the Breakthrough Therapy designation and progress to Phase 3, but also concerned about ongoing losses and the need for future capital raises.
• Employees may be motivated by the company's progress and the potential for its drug candidates to address unmet medical needs.
• Customers (potential patients) may benefit from the development of new treatments for MASH and other diseases.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Initiate the Phase 3 program for denifanstat by the end of 2024.
• Continue to advance the development of denifanstat in MASH.
• Monitor the results of Ascletis' Phase 3 clinical trials for acne and glioblastoma.
• Explore the use of FASN inhibitors in other disease areas.

Key Dates

Keywords

denifanstat, MASH, NASH, FASN inhibitor, clinical trials, Phase 3, Breakthrough Therapy, FDA, Ascletis, acne, glioblastoma, biopharmaceutical